Effect of gastric acid suppressants and prokinetics on peritoneal dialysis-related peritonitis

Table 4 Clinical characteristics of peritonitis patients by the causative pathogen n (%)

Variables	Included peritonitis episode (n = 81)
	Enteric peritonitis	Non-enteric peritonitis	P value
	(n = 26)	(n = 55)
Age (yr) [median (range)]	51.5 (29-69)	51.0 (27-79)	0.990
Sex (male)	16 (61.5)	27 (49.1)	0.295
Height (cm)	162.34 ± 7.88	162.21 ± 6.82	0.943
Bwt (kg)	56.93 ± 7.88	57.95 ± 8.50	0.610
BMI [m/(kg)2]	21.61 ± 2.68	22.05 ± 2.81	0.504
Cause of ESRD
Glomerulonephritis	12 (46.2)	17 (30.9)	0.250
DM	7 (26.9)	20 (36.4)
HTN	3 (11.5)	3 (5.5)
Polycystic kidney disease	0 (0.0)	1 (1.8)
Unknown/idiopathic	3 (11.5)	11 (20.0)
Other cause	1 (3.8)	3 (5.5)
HTN	21 (80.8)	43 (78.2)	0.789
DM	8 (30.8)	25 (45.5)	0.209
Diverticulosis	0 (0.0)	0 (0.0)
PD modality (CAPD)	23 (88.5)	46 (83.6)	0.743
Initial serum Albumin (mg/dL)	3.52 ± 0.45	3.47 ± 0.43	0.687
Peritonitis free time (d)
[median (range)]	692 (31–3696)	1064 (31-5383)	0.380

Data presented as mean ± SD, unless otherwise stated. Bwt: Body weight; BMI: Body mass index; ESRD: End stage renal disease; DM: Diabetes mellitus; HTN: Hypertension; LC: Liver cirrhosis; PD: Peritoneal dialysis; CAPD: Continuous ambulatory peritoneal dialysis.